- Home
- CR vs CORT Comparison
CR vs CORT Comparison
Compare CR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- CORT
- Stock Information
- Founded
- CR 1855
- CORT 1998
- Country
- CR United States
- CORT United States
- Employees
- CR N/A
- CORT N/A
- Industry
- CR Metal Fabrications
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- CR Industrials
- CORT Health Care
- Exchange
- CR Nasdaq
- CORT Nasdaq
- Market Cap
- CR 10.4B
- CORT 8.8B
- IPO Year
- CR N/A
- CORT N/A
- Fundamental
- Price
- CR $179.36
- CORT $89.51
- Analyst Decision
- CR Strong Buy
- CORT Strong Buy
- Analyst Count
- CR 5
- CORT 4
- Target Price
- CR $222.20
- CORT $139.00
- AVG Volume (30 Days)
- CR 287.4K
- CORT 917.9K
- Earning Date
- CR 10-27-2025
- CORT 10-29-2025
- Dividend Yield
- CR 0.50%
- CORT N/A
- EPS Growth
- CR 44.57
- CORT N/A
- EPS
- CR 6.02
- CORT 1.11
- Revenue
- CR $2,227,200,000.00
- CORT $716,080,000.00
- Revenue This Year
- CR $10.69
- CORT $30.77
- Revenue Next Year
- CR $10.98
- CORT $37.75
- P/E Ratio
- CR $35.32
- CORT $81.04
- Revenue Growth
- CR 18.63
- CORT 25.71
- 52 Week Low
- CR $127.04
- CORT $42.01
- 52 Week High
- CR $203.89
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- CR 41.61
- CORT 77.49
- Support Level
- CR $178.05
- CORT $82.70
- Resistance Level
- CR $184.39
- CORT $90.71
- Average True Range (ATR)
- CR 3.80
- CORT 2.60
- MACD
- CR 0.18
- CORT 0.78
- Stochastic Oscillator
- CR 27.65
- CORT 94.53
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.